IVD Standards Landscape

An IVD standards list must follow the diagnostic claim

No single catalogue applies to every IVD. The relevant standards depend on the analyte or measurand, specimen, methodology, result, clinical purpose, patient population, user, setting, instrument, software, calibrators, controls, manufacturing processes and target jurisdictions.

This landscape identifies common candidates. MTL-305 — Using Standards for EU IVDR Compliance and MTL-307 — Using Standards for FDA IVD Compliance explain jurisdiction-specific application.

Define the complete IVD system

Identify whether the product is a reagent, calibrator, control material, specimen receptacle, instrument, software function, test kit or combined system. Define intended purpose, analyte, specimen, population, condition, result type, measuring range, cut-offs, user and environment.

• Qualitative, semi-quantitative or quantitative result.
• Central laboratory, point-of-care, near-patient, self-test or companion-diagnostic use.
• Single-use reagents, reusable components, calibrators and quality controls.
• Manual steps, automation, sample preparation and environmental conditions.
• Instrument, embedded software, application software, middleware and LIS interfaces.
• Claims for sensitivity, specificity, precision, range, stability and turnaround time.
• EU IVDR classification or FDA product code, class and pathway.

Use MTL-102 — Intended Purpose, Users and Use Environments to stabilise the definition.

Quality and risk standards form the foundation

These standards support the system around the assay, but they do not establish the diagnostic validity or performance of the claimed result.

Performance evaluation connects three evidence pillars

ISO 20916 supports clinical performance studies using specimens from human subjects. Other ISO, CLSI and jurisdiction-specific guidance may support study design and reporting. The final evidence strategy must fit the intended purpose, risk and claims rather than merely reproduce a standard protocol.

See MTL-119 — Clinical and Performance Evaluation for the integrated evidence model.

Select analytical-performance methods by claim

CLSI and ISO documents provide widely used approaches for analytical studies. FDA recognition and EU harmonisation must be checked separately and may be partial or edition-specific.

Use MTL-120 — Statistical Methods and Measurement Assurance to connect study design, uncertainty, sample size and acceptance criteria.

Address metrological traceability for quantitative results

ISO 17511 supports metrological traceability of values assigned to calibrators, trueness-control materials and human samples. Related standards cover reference-measurement procedures, reference materials and laboratory competence.

The manufacturer should define the calibration hierarchy, higher-order references where available, uncertainty contributions, commutability, lot assignment and limitations. Traceability to a reference does not by itself demonstrate clinical suitability or eliminate bias across specimens and measuring conditions.

Include instrument, software, usability and cybersecurity standards

IVD analysers may use the IEC 61010 family for safety requirements and IEC 61326-2-6 for EMC. Embedded and application software may use IEC 62304 lifecycle processes, supported by IEC 62366-1 usability engineering and appropriate cybersecurity standards such as IEC 81001-5-1.

Connected systems may also require standards for interoperability, network communication, health-data formats, wireless coexistence and privacy. See MTL-111 — Data, Connectivity and Interoperability, MTL-108 — Software Lifecycle and MTL-109 — Medical-device Cybersecurity.

Control information supplied, stability and specimen handling

The ISO 18113 series addresses information supplied by the manufacturer for IVD reagents and instruments. ISO 23640 supports stability evaluation of IVD reagents. Other standards may apply to specimen receptacles, collection devices, transport media, symbols, units and result reporting.

Stability evidence should cover claimed shelf life, transport, opened-container or in-use periods, onboard stability and relevant environmental excursions. Instructions must align with the conditions actually studied and with risk controls for collection, preparation, storage and interpretation.

See MTL-128 — Labelling and Information Supplied and MTL-125 — Packaging, Transport and Shelf Life.

Add product-specific standards and common specifications

Some IVD types have standards or regulatory common specifications addressing particular performance and safety expectations. Examples include ISO 15197 for blood-glucose monitoring systems, standards for self-testing and point-of-care systems, and standards for particular laboratory instruments or specimen containers.

EU common specifications may impose requirements where harmonised standards are absent or insufficient. FDA special controls and product-specific guidance may define evidence beyond general consensus standards. Search by analyte, technology, product code, intended use and clinical decision—not only by “IVD”.

Build a claim-to-standard applicability matrix

The matrix should distinguish standards used for the quality system, analytical method, clinical study, instrument, software and production. Each answers a different part of the conformity argument.

Examples of IVD standards sets

These examples are starting points. The manufacturer must justify the complete set for the specific product, claims and target markets.

Maintain standards and performance evidence together

Monitor standards revisions, EU harmonisation, FDA recognition, CLSI updates, common specifications, guidance and scientific state of the art. Assess changes alongside reagent lots, calibrators, instruments, software, suppliers, specimen knowledge and post-market performance.

Complaints, invalid-result trends, external-quality information, bias shifts, new interferents and literature may require a revised method, additional study, labelling change or regulatory assessment. Use MTL-129 — Configuration and Change Management to control the decision.

Common misconceptions

Practical checklist

• Define the complete IVD system and every intended-use claim.
• Confirm EU classification or FDA product code, class and pathway.
• Separate quality, risk, analytical, clinical, instrument, software and production evidence.
• Create a standards longlist from technology, claims and regulatory sources.
• Check scope, edition, EU harmonisation and FDA recognition.
• Map methods to specimens, populations, ranges, statistics and acceptance criteria.
• Document deviations, adaptations and supplementary evidence.
• Connect conclusions to risk controls, labelling and post-market follow-up.
• Maintain the matrix throughout the product lifecycle.